Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (24,067)	$ (30,910)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,964	1,963
Noncash lease expense	290	288
Stock-based compensation expense	2,530	3,276
Change in fair value of common stock warrants	(30)	(508)
Change in fair value of contingent consideration	(712)	(731)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	113	(139)
Accounts payable	(1,477)	(235)
Accrued compensation	947	(277)
Accrued clinical trial site costs	(198)	(369)
Operating lease liabilities	(302)	(263)
Other liabilities	161	135
Net cash used in operating activities	(20,781)	(27,770)
Cash flows from investing activities:
Purchases of property and equipment	(13)	(22)
Net cash used in investing activities	(13)	(22)
Cash flows from financing activities:
Gross proceeds from sale of common stock and common stock warrants	15,152
Payment of issuance costs	(1,044)
Tax withholding payments for net share-settled equity awards	(16)	(120)
Principal paid on finance lease liabilities		(8)
Net cash (used in) provided by financing activities	14,092	(128)
Net decrease in cash and cash equivalents	(6,702)	(27,920)
Cash and cash equivalents, beginning of period	21,304	49,224
Cash and cash equivalents, end of period	$ 14,602	21,304
Supplemental disclosure of non-cash investing and financing information
Right-of use assets obtained in exchange for operating lease obligations		$ 581